Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 83

Cited In for PubMed (Select 15292538)

1.

Predictors of frequent recourse to health professionals by people with severe mental disorders.

Fleury MJ, Grenier G, Bamvita JM.

Can J Psychiatry. 2015 Feb;60(2):77-86.

2.

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients.

Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C.

Drugs Context. 2015 Mar 17;4. pii: 212267. doi: 10.7573/dic.212267. eCollection 2015.

3.

Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia.

Eticha T, Teklu A, Ali D, Solomon G, Alemayehu A.

PLoS One. 2015 Mar 27;10(3):e0120560. doi: 10.1371/journal.pone.0120560. eCollection 2015.

4.

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia.

Zhang F, Si T, Chiou CF, Harris AW, Kim CY, Jahagirdar P, Ascher S.

Neuropsychiatr Dis Treat. 2015 Mar 11;11:657-68. doi: 10.2147/NDT.S77778. eCollection 2015.

5.

Money for medication: a randomized controlled study on the effectiveness of financial incentives to improve medication adherence in patients with psychotic disorders.

Noordraven EL, Audier CH, Staring AB, Wierdsma AI, Blanken P, van der Hoorn BE, Roijen LH, Mulder CL.

BMC Psychiatry. 2014 Dec 2;14:343. doi: 10.1186/s12888-014-0343-3.

6.

Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study.

Degli Esposti L, Sangiorgi D, Mencacci C, Spina E, Pasina C, Alacqua M, la Tour F.

BMC Psychiatry. 2014 Oct 14;14:282. doi: 10.1186/s12888-014-0282-z.

8.

Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.

Haddad PM, Brain C, Scott J.

Patient Relat Outcome Meas. 2014 Jun 23;5:43-62. doi: 10.2147/PROM.S42735. eCollection 2014. Review.

9.

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection.

Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H.

Neuropsychiatr Dis Treat. 2014 Jun 20;10:1125-31. doi: 10.2147/NDT.S61409. eCollection 2014.

10.

The frequency of rehospitalization and associated factors in Colombian psychiatric patients: a cohort study.

Jaramillo-Gonzalez LE, Sanchez-Pedraza R, Herazo MI.

BMC Psychiatry. 2014 Jun 2;14:161. doi: 10.1186/1471-244X-14-161.

11.

Factors associated with early response to olanzapine and clinical and functional outcomes of early responders treated for schizophrenia in the People's Republic of China.

Ye W, Montgomery W, Kadziola Z, Liu L, Xue H, Stensland MD, Treuer T.

Neuropsychiatr Dis Treat. 2014 May 16;10:869-78. doi: 10.2147/NDT.S59468. eCollection 2014.

12.
13.

Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder.

Karve S, Markowitz M, Fu DJ, Lindenmayer JP, Wang CC, Candrilli SD, Alphs L.

Appl Health Econ Health Policy. 2014 Jun;12(3):335-46. doi: 10.1007/s40258-014-0095-8.

14.

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L.

BMC Psychiatry. 2013 Dec 20;13:340. doi: 10.1186/1471-244X-13-340.

15.

Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M.

Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18. doi: 10.1177/2045125312474019.

16.

Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review.

Olivares JM, Sermon J, Hemels M, Schreiner A.

Ann Gen Psychiatry. 2013 Oct 23;12(1):32. doi: 10.1186/1744-859X-12-32.

17.

Antipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalization.

Markowitz M, Karve S, Panish J, Candrilli SD, Alphs L.

BMC Psychiatry. 2013 Oct 5;13:246. doi: 10.1186/1471-244X-13-246.

18.

The personal, societal, and economic burden of schizophrenia in the People's Republic of China: implications for antipsychotic therapy.

Montgomery W, Liu L, Stensland MD, Xue HB, Treuer T, Ascher-Svanum H.

Clinicoecon Outcomes Res. 2013 Aug 14;5:407-18. doi: 10.2147/CEOR.S44325. eCollection 2013.

19.

A randomized controlled trial with a Canadian electronic pill dispenser used to measure and improve medication adherence in patients with schizophrenia.

Stip E, Vincent PD, Sablier J, Guevremont C, Zhornitsky S, Tranulis C.

Front Pharmacol. 2013 Aug 9;4:100. doi: 10.3389/fphar.2013.00100. eCollection 2013.

20.

Self-disorders and schizophrenia: a phenomenological reappraisal of poor insight and noncompliance.

Henriksen MG, Parnas J.

Schizophr Bull. 2014 May;40(3):542-7. doi: 10.1093/schbul/sbt087. Epub 2013 Jun 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk